Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Amaranth Medical

Request full access

Bioresorbable scaffolds for interventional cardiology procedures

Mountain View, United StatesFounded 2005Biotech & Life Sciences

About Amaranth Medical

Amaranth Medical was a medical device company that developed a technology platform for fully bioresorbable scaffolds aimed at the interventional cardiology market. Founded in 2006 by F. Freddy Boey and S. Subbu Venkatraman, the Mountain View-based firm focused on creating coronary stents that could provide mechanical support to an artery after a procedure and then gradually and predictably dissolve, leaving the vessel healed and free from a permanent metal implant. The company's stated mission was to improve long-term patient health by eliminating the clinical limitations associated with permanent stents.

The company's product pipeline included several scaffolds with progressively thinner struts, designed to mimic the performance of best-in-class metallic drug-eluting stents. Key products included the FORTITUDE, APTITUDE, and MAGNITUDE scaffolds. The FORTITUDE scaffold, its lead product, was designed to offer the high radial strength of metal stents while being fully bioresorbable. Amaranth successfully completed first-in-human studies and several international clinical trials for its sirolimus-eluting scaffolds, such as RENASCENT-I, RENASCENT-II, and MEND-II, with plans to seek a CE mark for commercialization in Europe.

Throughout its operation, Amaranth Medical raised significant capital, including a $20 million Series B round in 2013 from investors such as EDBI, Charter Life Sciences, and Phillip Capital. In 2014, it secured an additional equity investment from Boston Scientific to further advance clinical development and pursue CE marking. The company was led by CEO and CTO Kamal Ramzipoor, who emphasized the unique capabilities of Amaranth's proprietary polymer technology in creating thinner, stronger, and more flexible scaffolds compared to competitors. Despite its technological advancements and promising clinical data, the company ceased operations, and its assets were sold in a negotiated sale during an Assignment for the Benefit of Creditors, which was finalized around February 2019.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.0/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2C

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Oct 2013 $20M $80M PhillipCapital · Charter Life Sciences · Bio*One Capital · DCP Management —
SERIES A✓Equity / VC Sep 2006 $7.5M $30M Bio*One Capital · Charter Life Sciences · EDBI —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Amaranth Medical website traffic

Latest recorded traffic for Amaranth Medical is 110 monthly website visits, up 57.1% over the last three months.

Latest monthly visits110 3-month web change+57.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Amaranth Medical in the Mountain View ecosystem

Live from Dealroom

The Amaranth Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Bio*One Capital

Series A4 investors entered at this stage

  • EDBI
  • Charter Life Sciences
  • PhillipCapital
  • DCP Management

Other known investors1 additional known investor

  • Massachusetts Institute of Technology
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Mountain View HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Amaranth Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amaranth Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.